478 results about "Serology" patented technology

The invention provides proteins from Neisseria meningitidis (strains A & B), including amino acid sequences, the corresponding nucleotide sequences, expression data, and serological data. The proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics.

The present invention is related to methods of early diagnosis of ovarian cancer in a patient by determining serum levels of blood markers using a novel LabMAP™ technology (Luminex Corp., Austin, Tex.), which allows for simultaneous measurement of the blood markers in serum. The panel of blood markers offers extremely high predictive power for discrimination of ovarian cancer from both healthy control patients and from patients with benign pelvic/ovarian tumors. The methods of the present invention allow for rapid, early diagnosis of ovarian cancer with extremely high sensitivity and specificity to be clinically useful in disease diagnosis.

Sequences encoding two immunoreactive glycoproteins were cloned from Ehrlichia canis (p153 gene) and Ehrlichia chaffeensis (p156 gene). These two glycoproteins are species-specific immunoreactive orthologs that are useful as subunit vaccines and for serologic and molecular diagnostics for E. canis and E. chaffeensis.

The invention discloses a GeXP rapid detection kit capable of simultaneously identifying nine pathogens of chicken respiratory tract diseases. The kit is used based on a GeXP system and comprises ten polymerase chain reaction (PCR) primer pairs; the kit is used for identifying and detecting avian influenza virus, H5, H7 and H9 subtype avian influenza virus, newcastle disease virus, infectious bronchitis, infectious laryngotracheitis, mycoplasma gallisepticum, bursa synovialis mycoplasma and haemophilus paragallinarum; and the kit is good in specificity, high in sensitivity and can detect 100 copy/mu l. Compared with an identifying result of the conventional experiment method of a pathogen separation and hemagglutination inhibition experiment or a serology experiment and the like, the GeXP rapid detection kit has the advantage that the coincidence rate reaches 100 percent. The kit is generally used for detecting the main chicken respiratory tract diseases and the pathogens thereof, so that a simple and high-flux detection kit and a detection system are provided, an actual requirement is met, and the application prospect is wide.

The invention discloses a genetic engineering marked attenuated vaccine strain of a porcine reproductive and respiratory syndrome virus (PRRSV). The attenuated vaccine strain comprises a genomic nucleic acid of a porcine reproductive and respiratory syndrome virus attenuated vaccine strain HuN4-F112; the HuN4-F112 genome includes a mutation in a genetic region for coding an Nsp2 protein, and the mutation is as follows: a nucleotide sequence for coding a Newcastle disease virus NP protein is inserted to a lacking region of a nucleotide sequence for coding 480-532-site amino acid of the Nsp2 protein; or the nucleotide sequence for coding the Newcastle disease virus NP protein is inserted to the lacking region of a nucleotide sequence for coding 508-532-site amino acid of the Nsp2 protein. The invention also discloses an application of the genetic engineering marked attenuated vaccine strain. The genetic engineering marked attenuated vaccine strain of the porcine reproductive and respiratory syndrome virus provided by the invention not only can provide completely safe immune protection to resist high-pathogenicity PRRSV after the porcine is immunized, but also can effectively distinguish the immunized porcine of the porcine reproductive and respiratory syndrome vaccine with the naturally infected porcine of the field virus.

The invention provides a four-autoantibody combined detection kit for diagnosing an early esophageal squamous cancer and application thereof. The four-autoantibody combined detection kit for diagnosing the early esophageal squamous cancer comprises a solid substrate and antigen protein which coats the solid substrate; and the antigen protein comprises TP53, HRAS, CTAG1A and NSG1. The four-autoantibody combined detection kit for diagnosing the early esophageal squamous cancer, provided by the invention, has the advantages that the TP53, the HRAS, the CTAG1A and the NSG1 are firstly adopted as acombination to be used for early diagnosis of ESCC, higher sensibility and higher specificity are realized, the detection kit is conducive to further improvement of serologic screening quality of ESCC early diagnosis, and therefore, the cure rate and survival rate of patients are further promoted.

The invention provides proteins from gonococcus (Neisseria gonorrhoeae), including amino acid sequences, the corresponding nucleotide sequences, expression data, and serological data. The proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics. They are also useful for distinguishing between gonococcus and meningococcus and, in particular, between gonococcus and serogroup B meningococcus.

The invention discloses an indirect ELISA (enzyme linked immunosorbent assay) kit for detecting a porcine epidemic diarrhea virus antibody. The indirect ELISA kit comprises a coated ELISA plate, negative control serum, positive control serum, ELISA secondary antibody, a concentrated cleaning solution, a sample diluent, a developing liquid and a stop buffer, wherein the coated ELISA plate utilizes recombinant protein Nh as a coating antigen. Research and practice show that the indirect ELISA kit has the characteristics of high specificity and sensitiveness, simplicity in operation and the like, is easy to popularize and use in a large range, has a broad market prospect, and can be used for the fields of serological investigation, antibody monitoring and vaccine immunity effect evaluation and the like of epidemic diarrhea infection condition.

The present invention discloses a chimeric alphavirus comprising a Sindbis virus cDNA fragment, an Eastern equine encephalitis virus cDNA fragment, a Western equine encephalitis virus cDNA fragment or a combination thereof. The present also discloses the use of this chimeric alphavirus as vaccines and in serological and diagnostic assays.

The invention provides a human papillomavirus HPV DNA fragment, a mix primer for human papillomavirus HPV DNA detection and/ or parting and application thereof. The mixed primer can specifically amplify to obtain one or a plurality of DNA sequences from HPV6, HPV 11, HPV 16, HPV 18, HPV 26, HPV 31, HPV 33, HPV 35, HPV 39, HPV 40, HPV 42, HPV 43, HPV 44, HPV45, HPV 51, HPV 52, HPV 53, HPV 54, HPV 55, HPV 56, HPV 58, HPV 59, HPV 61, HPV 66, HPV 68, HPV 70, HPV 72, HPV 73, HPV 81, HPV 82 and HPV 83, can be used for the human papillomavirus HPV DNA detection and/ or parting and prepared into a PCR kit. The invention can detect common types of HPV at a time, greatly improve the HPV detection efficiency, overcome the defect of missed detection of latent infection by a serology and IHC detection method, realize early diagnosis of HPV diseases, and is suitable for clinical HPV gene detection and parting and guides prevention and cure of cervical carcinoma.

Disclosed are methods, protocols, and compositions of matter related to utilization of chimeric antigen receptor (CAR) expressing cells for the targeting of tumor endothelium utilizing chimeric antigen receptor expressing stem cells. In one embodiment tumor endothelium specific antigens are utilized as targets of the antigen binding domain of a CAR, which is attached to an extracellular hinge domain, a domain that transverses the T cell membrane and an intracellular domain associated with T cell signaling. Suitable antigens for the practice of the invention include TEM-1, ROBO-4, surviving, and FasL. In other aspects of the invention antigens are identified through serological analysis of recombinant cDNA expression libraries (SEREX) using plasma from a patient immunized with placental endothelial cells.

The invention discloses an immunogenic protein in a schistosoma japonicum soluble egg antigen. The immunogenic protein is selected from amino acid sequences shown in SEQ ID NO:2-SEQ ID NO:14. In addition, the invention also discloses a screening method and application of the immunogenic protein in the schistosoma japonicum soluble egg antigen and is mainly characterized by screening the immunogenic protein in the schistosoma japonicum soluble egg antigen through a combined proteomics technology and a serological method, particularly analyzing the immunogenic protein in the schistosoma japonicum soluble egg antigen by utilizing bidirectional electrophoresis, Westernblot (2D-WB) and a mass spectrum method and using the immunogenic protein as a potential target spot for schistosomiasis diagnosis.

The invention discloses a method for obtaining sogatella furcifera carrying SRBSDV (southern rice black-streaked dwarf virus) and an application sogatella furcifera. The method for obtaining the sogatella furcifera carrying the SRBSDV, comprises the following steps of: feeding the sogatella furcifera by utilizing rice infecting the SRBSDV or cryopreserved rice diseased plant so that the sogatella furcifera obtains the SRBSDV, transferring the infected sogatella furcifera to a healthy rice to be fed till passing through a circulation period of virus, and detecting the sogatella furcifera by utilizing an RT-PCR (reverse transcription-polymerase chain reaction) technology and a serology method to obtain the sogatella furcifera carrying the SRBSDV, wherein the carrier rate of the sogatella furcifera can reach more than 50% through a manual feeding manner based on the experiment. Through utilizing the method for obtaining the sogatella furcifera carrying the SRBSDV, the obtained sogatella furcifera carrying the SRBSDV can be applied to screening of SRBSDV-resisting monoclonal antibody to carry out a rice inoculation experiment to identify the resistance of the rice, screen disease-resistant variety and provide a service of the breeding for disease resistance. The invention can be further applied to researching mutual relation between the SRBSDV and a vector insect sogatella furcifera and provides powerful theoretical evidence for prevention and treatment on the viruses.

The invention discloses an indirect enzyme-linked immuno sorbent assay (ELISA) kit for detecting avian infectious bronchitis virus (IBV) antibody. The kit contains an ELISA plate enveloped by IBV-N recombinant protein serving as antigen. The IBV-N recombinant protein is obtained by the following method: designing a pair of specific primers according to an IBV-N gene sequence; amplifying the N gene of IBV by using a reverse transcription polymerase chain reaction (RT-PCR) method, directionally inserting the N gene into a pET-32a(+) expression vector, and screening to obtain a positive recombinant expression plasmid of pET-32a(+)-IBV-N; and transferring the plasmid to a BL21 competent cell, and performing isopropyl thiogalactoside (ITPG) induction expression to obtain the IBV-N recombinant protein. The kit is low in cost, easy, convenient and quick to operate, and particularly suitable for detecting batch samples, and greatly improves the efficiency of serodiagnosis of the avian infectious bronchitis.

The present invention provides a recombinant turkey herpesvirus modified by the presence of the cDNA encoding the hemagglutinin protein of avian influenza virus under a promoter. A poultry vaccine comprising the recombinant turkey herpesvirus described in the present invention can induce serological responses that may be easily detected by the hemagglutination inhibition assay but not by commercially available diagnostic ELISA kits; thus enabling easy differentiation between vaccination and field infection.

A method for preparing EB viral protein enzyme-linked immunosorbent diagnostic kit includes selectng EBNAl (BKRF1) prote, Zta (BZLF1) protein and VCA-p18 protin in EB viral protein for diagnosing nasopharyngeal carcinoma of serodiagnosis as target antigen for detecting antibody level in blood serum, using glutathione-transferase gene fusion system to carry on clone, presentation and purification of EB viral protein for creating diagnostic kit.

The invention discloses a nucleic acid aptamer specifically combined with a hepatitis C virus core protein and application thereof. The nucleic acid aptamer is a single stranded DNA shown in a sequence 2 of a sequence table or single stranded DNA containing the nucleic acid aptamer. The nucleic acid aptamer has better affinity with a hepatitis C virus core protein. By using the nucleic acid aptamer disclosed by the invention, the hepatitis C virus core protein in a solution can be captured and can be also detected, and hepatitis C serodiagnosis and blood screening can be realized. Part of thenucleic acid aptamer disclosed by the invention can be used to replace a monoclonal antibody to capture the core protein for hepatitis C detection. The invention has the advantages of high sensitivity, low cost, easiness of preparation and storage, and high application value.

The invention relates to a preparation method for an African swine fever virus (ASFV) antibody detection colloidal gold immunochromatography test paper strip, belonging to the field of bioengineering and animal epidemic disease diagnosis. The preparation method comprises the following steps of: expressing an ASFV recombinant antigen p54, purifying, preparing an antibody, preparing a colloidal gold immunochromatography test paper strip, and detecting the sensitivity and specificity of the ASFV antibody. Compared with the other conventional serological methods, the colloidal gold immunochromatography test paper strip prepared by the method has the advantages of convenience, quickness, sensitivity, specificity and the like, can be used for obtaining a definite diagnosis result within 5 minutes and directly detecting a suspicious swine serum (or anticoagulation) virus antibody, and is particularly suitable for field ASFV serological diagnosis, epidemiological survey and swine international trade quarantine and inspection.

The invention belongs to the fields of immunology and biotechnology, and particularly relates to a PSMD4 protein ELISA detection kit as well as a detection method and application to serological diagnosis for liver cancer of the kit. According to extensive and deep research of the inventor, the expression level of PSMD4 protein in the serum of liver cancer patients can be detected according to an enzyme-linked immunosorbent assay (ELISA) method, and the PSMD4 protein is proved for the first time in the serum of the liver cancer patients. The kit comprises an ELISA plate coated with a PSMD4 antibody, a PSMD4 antigen detection antibody, an ELIAS secondary antibody, standard protein and the like. The invention further provides the detection method and application of the kit. The kit is simple and convenient to operate, can detect the content of the PSMD4 protein in the serum of a liver cancer patient correctly and highly sensitively, and provides a novel method for clinical examination and basic research.

The invention discloses dominant epitope antigens of hemagglutinin (HA) and neuraminidase (NA) of human infection with H7N9 avian influenza, and further discloses the applications of the antigens in an antibody detection reagent of human infection with H7N9 avian influenza. According to the epitope antigens of human infection with H7N9 avian influenza and the applications of epitope antigens in immune detection reagent, bioinformatics technology is employed to analyze the existing HA and NA sequences of H7N9, four antigen sections are screened to be cloned and expressed, the sensitivity and sensitivity of the antigens are screened by serological tests, and the third antigen is finally determined to have the highest diagnostic value so as to be applicable to detect the antibody of human infection with H7N9 avian influenza.

The invention provides a group I FAdV-4 (fowl adenovirus serotype 4) vaccine. An antigen of the group I FAdV-4 vaccine is an inactivated YBAV-4 virus. According to the prepared group I FAdV-4 inactivated vaccine, the immune effect of the vaccine is evaluated with a serology method and a vaccinated challenge method, a result shows that the prepared fowl adenovirus inactivated vaccine can provide effective immune protection for fowls, and the group I FAdV-4 inactivated vaccine has a good commercial development prospect.